Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
4/28/2026, 12:00:00 AM
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
Korean Translation
미국 FDA가 HIV 치료 후보 약물인 도라비린/이슬라트라비르의 신약 허가 신청(NDA)에 대한 PDUFA 목표일을 2026년 4월 28일로 지정함. 신약 승인은 보통 5-10%의 주가 영향을 미칠 것으로 예상됨, 예정됨.
Related Recent Events
Murphy Oil Corp (MUR) · Earnings Release
The company is expected to release its Q1 2026 earnings results on or around May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Sysco Corporation (SYY) · Earnings Release
Sysco's Q3 2026 earnings release is expected on or around May 5, 2026, based on past reporting schedules. Analysts forecast an EPS of $0.95. High importance is estimated due to historical price volatility following earnings. This is scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
UPS Q1 2026 earnings release and conference call scheduled.
4/28/2026, 12:00:00 AM
Coca-Cola Co (The) (KO) · Earnings Release
First quarter 2026 earnings release on April 27, 2026, for which low importance is estimated due to typical market reaction to quarterly results, is scheduled.
4/27/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
AbbVie is scheduled to release its Q1 2026 financial results on April 24, 2026, with analysts forecasting EPS around $3.01-$3.02 and revenue of approximately $14.72 billion; Medium importance is estimated based on typical earnings price impact, scheduled.
4/24/2026, 12:00:00 AM